Tags

Type your tag names separated by a space and hit enter

Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials .
Int J Clin Pharmacol Ther 2019; 57(7):345-352IJ

Abstract

OBJECTIVES

We aimed to assess the relative efficacy and safety of once-daily administration of lesinurad in combination with xanthine oxidase inhibitor (XOI) in hyperuricemic patients with gout.

MATERIALS AND METHODS

A Bayesian random-effects network meta-analysis was performed to combine the direct and indirect evidence from randomized controlled trials (RCTs) for evaluating the efficacy and safety of lesinurad 200 mg + XOI, lesinurad 400 mg + XOI, and XOI monotherapy in hyperuricemic patients with gout.

RESULTS

Three RCTs including a total of 1,537 patients fulfilled the inclusion criteria. The number of patients who had achieved a target serum uric acid (sUA) level was significantly higher in the lesinurad 40 mg + XOI and lesinurad 200 mg + XOI groups than in the XOI monotherapy group (R 4.55, 95% credible interval (CrI) 2.13 - 9.81 and OR 2.78, 95% CrI 1.28 - 5.71, respectively). The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that lesinurad 400 mg + XOI was more likely to achieve the best target sUA level (SUCRA = 0.968), followed by lesinurad 200 mg + XOI (SUCRA = 0.526), and XOI (SUCRA = 0.006). The frequency of treatment-emergent adverse events (TEAEs) in the XOI group was significantly lower than that in the lesinurad 400 mg + XOI group (OR 0.59, 95% CrI 0.39 - 0.90).

CONCLUSION

Lesinurad 200 mg + XOI and lesinurad 400 mg + XOI were more effective than XOI for hyperuricemic patients with gout, but lesinurad 400 mg + XOI had a significant risk of TEAE development.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

30990408

Citation

Song, Gwan Gyu, and Young Ho Lee. "Comparative Efficacy and Safety of Lesinurad 200 Mg and 400 Mg Combined With a Xanthine Oxidase Inhibitor in Hyperuricemic Patients With Gout: a Bayesian Network Meta-analysis of Randomized Controlled Trials ." International Journal of Clinical Pharmacology and Therapeutics, vol. 57, no. 7, 2019, pp. 345-352.
Song GG, Lee YH. Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials . Int J Clin Pharmacol Ther. 2019;57(7):345-352.
Song, G. G., & Lee, Y. H. (2019). Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials . International Journal of Clinical Pharmacology and Therapeutics, 57(7), pp. 345-352. doi:10.5414/CP203425.
Song GG, Lee YH. Comparative Efficacy and Safety of Lesinurad 200 Mg and 400 Mg Combined With a Xanthine Oxidase Inhibitor in Hyperuricemic Patients With Gout: a Bayesian Network Meta-analysis of Randomized Controlled Trials. Int J Clin Pharmacol Ther. 2019;57(7):345-352. PubMed PMID: 30990408.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials . AU - Song,Gwan Gyu, AU - Lee,Young Ho, PY - 2019/06/25/accepted PY - 2019/4/17/pubmed PY - 2019/8/6/medline PY - 2019/4/17/entrez SP - 345 EP - 352 JF - International journal of clinical pharmacology and therapeutics JO - Int J Clin Pharmacol Ther VL - 57 IS - 7 N2 - OBJECTIVES: We aimed to assess the relative efficacy and safety of once-daily administration of lesinurad in combination with xanthine oxidase inhibitor (XOI) in hyperuricemic patients with gout. MATERIALS AND METHODS: A Bayesian random-effects network meta-analysis was performed to combine the direct and indirect evidence from randomized controlled trials (RCTs) for evaluating the efficacy and safety of lesinurad 200 mg + XOI, lesinurad 400 mg + XOI, and XOI monotherapy in hyperuricemic patients with gout. RESULTS: Three RCTs including a total of 1,537 patients fulfilled the inclusion criteria. The number of patients who had achieved a target serum uric acid (sUA) level was significantly higher in the lesinurad 40 mg + XOI and lesinurad 200 mg + XOI groups than in the XOI monotherapy group (R 4.55, 95% credible interval (CrI) 2.13 - 9.81 and OR 2.78, 95% CrI 1.28 - 5.71, respectively). The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that lesinurad 400 mg + XOI was more likely to achieve the best target sUA level (SUCRA = 0.968), followed by lesinurad 200 mg + XOI (SUCRA = 0.526), and XOI (SUCRA = 0.006). The frequency of treatment-emergent adverse events (TEAEs) in the XOI group was significantly lower than that in the lesinurad 400 mg + XOI group (OR 0.59, 95% CrI 0.39 - 0.90). CONCLUSION: Lesinurad 200 mg + XOI and lesinurad 400 mg + XOI were more effective than XOI for hyperuricemic patients with gout, but lesinurad 400 mg + XOI had a significant risk of TEAE development. SN - 0946-1965 UR - https://www.unboundmedicine.com/medline/citation/30990408/Comparative_efficacy_and_safety_of_lesinurad_200_mg_and_400_mg_combined_with_a_xanthine_oxidase_inhibitor_in_hyperuricemic_patients_with_gout:_A_Bayesian_network_meta-analysis_of_randomized_controlled_trials_ L2 - https://www.dustri.com/nc/journals-in-english?artId=18280 DB - PRIME DP - Unbound Medicine ER -